Benefits of Mounjaro (Tirzepatide) for Type 2 Diabetes

Glycemic Control and Weight Loss Benefits

• The American Diabetes Association recommends tirzepatide as a preferred agent for early use in type 2 diabetes with cardiovascular disease risk factors and/or obesity, with HbA1c reductions of 1.87-2.59% and weight loss of 6.2-12.9 kg 1

Cardiovascular and Safety Profile

• Compared with usual care, tirzepatide does not reduce all-cause mortality, with low to high certainty of evidence 2

Important Clinical Considerations

• Tirzepatide carries a low risk of hypoglycemia when used appropriately, with significantly lower risk compared to insulin and sulfonylureas, and may increase risk for malnutrition and sarcopenia with significant weight loss 1
• Delays gastric emptying, which increases aspiration risk during anesthesia, a critical perioperative consideration 1
• Screen patients experiencing rapid weight loss or significant weight loss for complications 1